Advances of Zebrafish in Neurodegenerative Disease: From Models to Drug Discovery

64Citations
Citations of this article
170Readers
Mendeley users who have this article in their library.

Abstract

Neurodegenerative disease (NDD), including Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis, are characterized by the progressive loss of neurons which leads to the decline of motor and/or cognitive function. Currently, the prevalence of NDD is rapidly increasing in the aging population. However, valid drugs or treatment for NDD are still lacking. The clinical heterogeneity and complex pathogenesis of NDD pose a great challenge for the development of disease-modifying therapies. Numerous animal models have been generated to mimic the pathological conditions of these diseases for drug discovery. Among them, zebrafish (Danio rerio) models are progressively emerging and becoming a powerful tool for in vivo study of NDD. Extensive use of zebrafish in pharmacology research or drug screening is due to the high conserved evolution and 87% homology to humans. In this review, we summarize the zebrafish models used in NDD studies, and highlight the recent findings on pharmacological targets for NDD treatment. As high-throughput platforms in zebrafish research have rapidly developed in recent years, we also discuss the application prospects of these new technologies in future NDD research.

Cite

CITATION STYLE

APA

Wang, X., Zhang, J. B., He, K. J., Wang, F., & Liu, C. F. (2021, July 14). Advances of Zebrafish in Neurodegenerative Disease: From Models to Drug Discovery. Frontiers in Pharmacology. Frontiers Media S.A. https://doi.org/10.3389/fphar.2021.713963

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free